XPhyto Places First Order For 25-Minute COVID-19 RT-PCR Tests
Feb 24, 2021
Vancouver, Canada (February 24, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that it has...
XPhyto Builds Commercial Team To Launch 25-Minute COVID-19 RT-PCR Test
Feb 22, 2021
Vancouver, Canada (February 22, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...
XPhyto European CE-IVD Application For 25-Minute COVID-19 RT-PCR Test
Feb 16, 2021
Vancouver, Canada (February 16, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...
XPhyto Adds Mescaline Production To Psychedelic Medicine Programs
Feb 10, 2021
Vancouver, Canada (February 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...
XPhyto Announces Psychedelic Pharmaceutical Production Agreement
Feb 3, 2021
Vancouver, Canada (February 3, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...
XPhyto Announces Drug Formulation Strategy And 2021 Milestones
Jan 28, 2021
Construction of commercial drug manufacturing facility in GermanyFour clinical studies in neurological indications in 2021Development of oral biosensor and contract development & manufacturingPsychedelic transdermal and...
XPhyto Announces Business Strategy And Milestones For 2021
Jan 18, 2021
Commercialization of rapid COVID-19 PCR testClinical validation of transdermal and sublingual drug formulationsPsychedelic API production, drug formulation and clinical integration Vancouver, Canada (January 18, 2021)...
XPhyto Completes Successful SARS-COV-2 RT-PCR Diagnostic Test Kit Validation
Dec 17, 2020
Vancouver, Canada (December 17, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience accelerator, and its exclusive...
Exclusive Psychedelic Drug Development Agreement Secured
Nov 9, 2020
Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for the development of psychedelic-based therapeutics Vancouver, Canada (November 09, 2020)...
XPhyto Appoints European Healthcare Executive To Board Of Directors
Nov 4, 2020
Experienced pharma executive and consultant Per S. Thoresen joins boardAdvisory engagement with CorpCann AS strengthens Europe-focused strategy Vancouver, Canada (November 04, 2020) - XPhyto Therapeutics...
XPhyto Engages German Partner For Development Of Psilocybin API Production
Nov 3, 2020
Research agreement to investigate the feasibility of a proprietary biotechnology process for the industrial production of psilocybin APIPsilocybin is designated by the FDA as a...
XPhyto Announces RT-PCR Test For Point-Of-Care COVID-19 Detection
Oct 28, 2020
25-minute RT-PCR lab test to complement 15-minute rapid testEuropean market launch of both COVID-19 tests planned for Q1 2021 Vancouver, Canada (October 28, 2020) -...
